Skip to main content Skip to navigation
BV510 Mouse Anti-Human BCAM (CD239)
Product Details
Down Arrow Up Arrow


BD OptiBuild™
B-CAM; BCAM; Lutheran glycoprotein; MSK19
Human (Tested in Development)
Mouse C57BL/6 IgG2a, κ
Human BCAM Transfected Cell Line
Flow cytometry (Qualified)
0.2 mg/ml
AB_2872475
Aqueous buffered solution containing ≤0.09% sodium azide.
RUO


Preparation And Storage

Store undiluted at 4°C and protected from prolonged exposure to light. Do not freeze. The monoclonal antibody was purified from tissue culture supernatant or ascites by affinity chromatography. The antibody was conjugated with BD Horizon BV510 under optimal conditions that minimize unconjugated dye and antibody.

Recommended Assay Procedures

For optimal and reproducible results, BD Horizon Brilliant Stain Buffer should be used anytime two or more BD Horizon Brilliant dyes (including BD OptiBuild Brilliant reagents) are used in the same experiment.  Fluorescent dye interactions may cause staining artifacts which may affect data interpretation.  The BD Horizon Brilliant Stain Buffer was designed to minimize these interactions.  More information can be found in the Technical Data Sheet of the BD Horizon Brilliant Stain Buffer (Cat. No. 563794).

Product Notices

  1. This antibody was developed for use in flow cytometry.
  2. The production process underwent stringent testing and validation to assure that it generates a high-quality conjugate with consistent performance and specific binding activity. However, verification testing has not been performed on all conjugate lots.
  3. Researchers should determine the optimal concentration of this reagent for their individual applications.
  4. An isotype control should be used at the same concentration as the antibody of interest.
  5. Caution: Sodium azide yields highly toxic hydrazoic acid under acidic conditions. Dilute azide compounds in running water before discarding to avoid accumulation of potentially explosive deposits in plumbing.
  6. For fluorochrome spectra and suitable instrument settings, please refer to our Multicolor Flow Cytometry web page at www.bdbiosciences.com/colors.
  7. Please refer to www.bdbiosciences.com/us/s/resources for technical protocols.
  8. BD Horizon Brilliant Stain Buffer is covered by one or more of the following US patents: 8,110,673; 8,158,444; 8,575,303; 8,354,239.
  9. BD Horizon Brilliant Violet 510 is covered by one or more of the following US patents: 8,575,303; 8,354,239.
748014 Rev. 1
Antibody Details
Down Arrow Up Arrow
B64

The B64 monoclonal antibody specifically recognizes Basal Cell Adhesion Molecule (BCAM, B-CAM) which is also known as CD239, Lutheran blood group antigen (Lu), or Lutheran glycoprotein. BCAM (CD239) is a type I transmembrane glycoprotein that is encoded by BCAM [basal cell adhesion molecule (Lutheran blood group)] which belongs to the Ig gene superfamily. Full-length BCAM (CD239) is comprised of an extracellular region with two N-terminal V-type Ig-like domains followed by three C2-type Ig-like domains, a transmembrane region, and cytoplasmic domain of 59 amino acid residues. The extracellular region of this adhesion molecule functions as a receptor for α5-chain containing laminins which are found in basement membranes whereas its cytoplasmic tail may have signal-transduction functions. BCAM (CD239) is expressed on erythrocytes and on the basal layer of vascular endothelial cells or some epithelial cells. BCAM (CD239) is highly expressed on sickle red cells and may play a role in vaso-occlusive crises in sickle cell disease. It is also upregulated upon malignant transformation of some cell types including those found in ovarian carcinomas.

The antibody was conjugated to BD Horizon™ BV510 which is part of the BD Horizon Brilliant™ Violet family of dyes. With an Ex Max of 405-nm and Em Max at 510-nm, BD Horizon BV510 can be excited by the violet laser and detected in the BD Horizon V500 (525/50-nm) filter set. BD Horizon BV510 conjugates are useful for the detection of dim markers off the violet laser.

748014 Rev. 1
Format Details
Down Arrow Up Arrow
BV510
The BD Horizon Brilliant Violet™ 510 (BV510) Dye is part of the BD Horizon Brilliant Violet™ family of dyes. This polymer-technology based dye with an excitation maximum (Ex Max) at 327-nm / 405-nm and an emission maximum (Em Max) at 512-nm. BV510, driven by BD innovation, is designed to be excited by the violet laser (405-nm) and detected using an optical filter centered near 510-nm (e.g., a 525/50 bandpass filter). The dye can be excited by the UV (355-nm) laser resulting in cross-laser excitation and spillover. Please ensure that your instrument’s configurations (lasers and optical filters) are appropriate for this dye.
altImg
BV510
Violet 405 nm
327 nm, 405 nm
512 nm
748014 Rev.1
Citations & References
Down Arrow Up Arrow

Development References (4)

  1. Kikkawa Y, Miner JH. Review: Lutheran/B-CAM: a laminin receptor on red blood cells and in various tissues.. Connect Tissue Res. 2005; 46(4-5):193-9. View Reference
  2. Wautier MP, El Nemer W, Gane P, et al. Increased adhesion to endothelial cells of erythrocytes from patients with polycythemia vera is mediated by laminin alpha5 chain and Lu/BCAM.. Blood. 2007; 110(3):894-901. View Reference
  3. Zen Q, Cottman M, Truskey G, Fraser R, Telen MJ. Critical factors in basal cell adhesion molecule/lutheran-mediated adhesion to laminin.. J Biol Chem. 1999; 274(2):728-34. View Reference
  4. Zola H, Swart B, Nicholson I, Voss E. CD239. In: Zola H. Leukocyte and stromal cell molecules : the CD markers. Hoboken, N.J.: Wiley-Liss; 2007:393-394.
View All (4) View Less
748014 Rev. 1

Please refer to Support Documents for Quality Certificates


Global - Refer to manufacturer's instructions for use and related User Manuals and Technical data sheets before using this products as described


Comparisons, where applicable, are made against older BD Technology, manual methods or are general performance claims.  Comparisons are not made against non-BD technologies, unless otherwise noted.

For Research Use Only. Not for use in diagnostic or therapeutic procedures.